315 related articles for article (PubMed ID: 26831356)
1. Nationwide prospective and retrospective surveys for hepatitis B virus reactivation during immunosuppressive therapies.
Mochida S; Nakao M; Nakayama N; Uchida Y; Nagoshi S; Ido A; Mimura T; Harigai M; Kaneko H; Kobayashi H; Tsuchida T; Suzuki H; Ura N; Nakamura Y; Bessho M; Dan K; Kusumoto S; Sasaki Y; Fujii H; Suzuki F; Ikeda K; Yamamoto K; Takikawa H; Tsubouchi H; Mizokami M
J Gastroenterol; 2016 Oct; 51(10):999-1010. PubMed ID: 26831356
[TBL] [Abstract][Full Text] [Related]
2. Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan.
Fukuda W; Hanyu T; Katayama M; Mizuki S; Okada A; Miyata M; Handa Y; Hayashi M; Koyama Y; Arii K; Kitaori T; Hagiyama H; Urushidani Y; Yamasaki T; Ikeno Y; Suzuki T; Omoto A; Sugitani T; Morita S; Inokuma S
Ann Rheum Dis; 2017 Jun; 76(6):1051-1056. PubMed ID: 27934678
[TBL] [Abstract][Full Text] [Related]
3. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
Chen FW; Coyle L; Jones BE; Pattullo V
Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
[TBL] [Abstract][Full Text] [Related]
4. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
5. De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation.
Ueda Y; Marusawa H; Egawa H; Okamoto S; Ogura Y; Oike F; Nishijima N; Takada Y; Uemoto S; Chiba T
Antivir Ther; 2011; 16(4):479-87. PubMed ID: 21685535
[TBL] [Abstract][Full Text] [Related]
6. A Hospital-Based Analysis in the Department of Clinical Chemistry for the Patients with HBV Reactivation after Anti-Cancer or Immunosuppressive Therapy.
Matsuzaki T; Ohkubo K; Yuki M; Kawashima H; Matsunaga A
Rinsho Byori; 2015 Mar; 63(3):297-304. PubMed ID: 26524851
[TBL] [Abstract][Full Text] [Related]
7. Validity of administrative database detection of previously resolved hepatitis B virus in Japan.
Imai S; Yamana H; Inoue N; Akazawa M; Horiguchi H; Fushimi K; Migita K; Yatsuhashi H; Sugiyama M; Mizokami M
J Med Virol; 2019 Nov; 91(11):1944-1948. PubMed ID: 31283012
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus reactivation in patients with rheumatoid arthritis: Analysis of the National Database of Japan.
Fujita M; Sugiyama M; Sato Y; Nagashima K; Takahashi S; Mizokami M; Hata A
J Viral Hepat; 2018 Nov; 25(11):1312-1320. PubMed ID: 29770539
[TBL] [Abstract][Full Text] [Related]
9. Prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy.
Tamori A; Hino M; Kawamura E; Fujii H; Uchida-Kobayashi S; Morikawa H; Nakamae H; Enomoto M; Murakami Y; Kawada N
J Gastroenterol Hepatol; 2014 Sep; 29(9):1715-21. PubMed ID: 24730465
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study.
Seto WK; Chan TS; Hwang YY; Wong DK; Fung J; Liu KS; Gill H; Lam YF; Lie AK; Lai CL; Kwong YL; Yuen MF
J Clin Oncol; 2014 Nov; 32(33):3736-43. PubMed ID: 25287829
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving immunosuppressive therapy for glomerulonephritis: a retrospective analysis.
Fang J; Li W; Peng X; Tan Z; Tan M; Zhang C; Wang W; Xu Z; Zhou G
Int Urol Nephrol; 2017 Mar; 49(3):475-482. PubMed ID: 28032257
[TBL] [Abstract][Full Text] [Related]
12. Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations.
Piaserico S; Messina F; Russo FP
Am J Clin Dermatol; 2019 Dec; 20(6):829-845. PubMed ID: 31222626
[TBL] [Abstract][Full Text] [Related]
13. Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy.
Rodríguez-Tajes S; Miralpeix A; Costa J; López-Suñé E; Laguno M; Pocurull A; Lens S; Mariño Z; Forns X
J Viral Hepat; 2021 Jan; 28(1):89-94. PubMed ID: 32969557
[TBL] [Abstract][Full Text] [Related]
14. Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma.
Matsui T; Kang JH; Nojima M; Tomonari A; Aoki H; Yamazaki H; Yane K; Tsuji K; Andoh S; Andoh S; Sakai H; Maemori M; Maguchi H; Tanaka Y
J Med Virol; 2013 Nov; 85(11):1900-6. PubMed ID: 23926082
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy.
Hayashi K; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Tachi Y; Ishikawa T; Katano Y; Yoshioka K; Toyoda H; Kumada T; Goto H; Hirooka Y
J Gastroenterol; 2016 Nov; 51(11):1081-1089. PubMed ID: 26943169
[TBL] [Abstract][Full Text] [Related]
16. Incidence of Hepatitis B Virus Reactivation and Hepatotoxicity in Patients Receiving Long-term Treatment With Tumor Necrosis Factor Antagonists.
Pauly MP; Tucker LY; Szpakowski JL; Ready JB; Baer D; Hwang J; Lok AS
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1964-1973.e1. PubMed ID: 29702293
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression.
Salpini R; Colagrossi L; Bellocchi MC; Surdo M; Becker C; Alteri C; Aragri M; Ricciardi A; Armenia D; Pollicita M; Di Santo F; Carioti L; Louzoun Y; Mastroianni CM; Lichtner M; Paoloni M; Esposito M; D'Amore C; Marrone A; Marignani M; Sarrecchia C; Sarmati L; Andreoni M; Angelico M; Verheyen J; Perno CF; Svicher V
Hepatology; 2015 Mar; 61(3):823-33. PubMed ID: 25418031
[TBL] [Abstract][Full Text] [Related]
18. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
[TBL] [Abstract][Full Text] [Related]
19. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
[TBL] [Abstract][Full Text] [Related]
20. Reactivation of hepatitis B virus in hematopoietic stem cell transplant recipients in Japan: efficacy of nucleos(t)ide analogues for prevention and treatment.
Nakamoto S; Kanda T; Nakaseko C; Sakaida E; Ohwada C; Takeuchi M; Takeda Y; Mimura N; Iseki T; Wu S; Arai M; Imazeki F; Saito K; Shirasawa H; Yokosuka O
Int J Mol Sci; 2014 Nov; 15(11):21455-67. PubMed ID: 25421241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
